Pharmafile Logo
Pharmafocus logo
Advanced Search

Research and Development

Showing 15 posts of 9620 posts found.

stocks1

Weekly Movers: PTC Therapeutics, Celator Pharmaceuticals, Chiasma, Sarepta and more…

April 25, 2016 Research and Development, Sales and Marketing

With the earnings season in full swing this week investors focussed on the impact on stock moves as companies declared …
Feature

Pfizer, GSK’s anti-smoking drugs not linked to increase in serious neuropsychiatric adverse events – Study

April 25, 2016 Research and Development, Sales and Marketing

Pharma giant Pfizer’s (NYSE: PFE) smoking cessation drug Chantix (varenicline) did not show an increase in serious neuropsychiatric adverse events …
News
sample

Merck’s colorectal cancer drug meets primary endpoint in Phase III study

April 25, 2016 Research and Development, Sales and Marketing Erbitux, Merck, Serono, cancer drugs, colorectal cancer, increased survival, oncology, phase 3, phase III

Merck (FWB: MRK) has announced that its Phase III clinical trial of Erbitux, in combination with Folfox, met its primary …
News
trials

AbbVie announces further industry and academic collaborations

April 22, 2016 Medical Communications, Research and Development AbbVie, collaboration, commercialisation, cytomx, partnership, research, university of chicago

AbbVie (NYSE: ABBV) has announced further collaborations that will see it partner with industry and academia to develop oncology candidates …
News
lab

Novartis muscular drug fails in Phase III trials

April 22, 2016 Medical Communications, Research and Development FDA, Novartis, bimagrumab, breakthrough, morphosys, muscular, phase III

A muscular drug developed by Novartis (NYSE: NVS), in partnership with MorphoSys (ETR: MOR), failed to meet its primary endpoint …
News
blue_jeans

Bluebird Bio gene therapy posts encouraging results in treatment of rare brain disease

April 21, 2016 Medical Communications, Research and Development Bluebird Bio, Phase II, gene therapy, lenti-d, paediatric, phase 2, phase 3, phase III, rare brain disease

Bluebird bio (NASDAQ: BLUE) has announced positive interim data from a Phase II/III trial evaluating their Lenti-D gene therapy in …
News

PCI Pharma Services’ Ian Parsonage to Share Serialization Expertise at Global Track & Trace Conference

April 21, 2016 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing ian parsonage, pci pharma, serialisation

Ian Parsonage, Senior Director of Global Serialization for leading pharmaceutical services provider PCI Pharma Services, will present at the Global …
News
Press release
figures_charts

Shares plunge at Sarepta after negative FDA review on muscle disorder drug

April 21, 2016 Research and Development, Sales and Marketing FDA, Sarepta Therapeutics, Shares, dive, fall, negative, plunge, sarepta

Sarepta Therapeutics (NASDAQ: SPRT) is counting the cost as shares plunge following a negative review given by staff at the …
News
gwpharma

GW Pharma’s cannabis-based epilepsy drug granted orphan designation by FDA

April 21, 2016 Research and Development, Sales and Marketing GW Pharma, cannabis, cannabis-based, epilepsy

GW Pharmaceuticals (NASDAQ: GWPH) has announced that the US Food and Drug Administration has granted its cannabis-based epilepsy drug, Epidiolex …
News
afinitor_combo-front

Novartis drug Afinitor significantly reduces seizures in TSC patients

April 21, 2016 Research and Development Afinitor, Novartis, Tuberous Sclerosis Complex, drug, seizure, seizures, tsc

Novartis (SIX: NOVN) has announced the results from a Phase III clinical trial which shows that Afinitor (everolimus) significantly reduced …
News
clinicaltrial1

BioMarin announces positive data from early stage trials of haemophilia A gene therapy

April 21, 2016 Research and Development BioMarin Pharmaceutical, Phase II, drug trial, haemophilia A gene therapy

BioMarin Pharmaceutical (Nasdaq: BMRN) said early-stage trials for its haemophilia A gene therapy showed encouraging data. Chief Medical Officer, Hank …
News
amgen_flag

Amgen’s drug reduces rates of bleeding in rare childhood disorder

April 21, 2016 Research and Development, Sales and Marketing Amgen, blood disorder, children, nplate, paediatric, platelet, rare, romisplostim

Amgen (NASDAQ: AMGN) has announced the results of a Phase III trial, published in The Lancet, which shows that Nplate …
News
abbvie_0

Abbvie acquires immune-oncology target from argenx

April 21, 2016 Research and Development, Sales and Marketing AbbVie, Protein, argenx, garp, immuno-oncology, immunosuppresive

AbbVie (NYSE:ABBV) has announced the acquisition of a new preclinical-stage human antibody program evaluating the novel immune-oncology target GARP, a …
News

Illumina shares plunge as it cuts Q1 outlook

April 20, 2016 Research and Development, Sales and Marketing Financial, Illumina, Share price, Shares, outlook, revenue, stock market

Shares in Illumina (Nasdaq: ILMN) plunged after the company cut its revenue estimates for the first quarter based on low …
News
opdivo_1_1

Focus: Bristol-Myers Squibb’s wonder drug – Opdivo

April 20, 2016 Research and Development, Sales and Marketing BMS, growth, immuno-oncology, opdivo, sales

By Anjali ShuklaNew data for Bristol-Myers Squibb’s (NYSE: BMY) Opdivo to treat head and neck cancer showed superior survival compared with …
Feature
The Gateway to Local Adoption Series

Latest content

Study explores genomic testing approach for unexplained infertility

May 14, 2026

Celtic Renewables receives £7m to develop bio-based solvents

May 14, 2026

Synnovis and SOPHiA GENETICS expand liquid biopsy testing in NHS cancer care

May 13, 2026

MHRA to establish Northern Ireland hub for life sciences sector

May 13, 2026

Shilpa Medicare signs manufacturing deal with NXI Therapeutics

May 12, 2026